NCT06280768View on ClinicalTrials.gov

Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Atrial Fibrillation

Interventions

DRUG

SHR-2004 injection

dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY